41 studies found for:    " February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Biological: V526;   Biological: Comparator: Placebo to V526
2 Terminated
Has Results
Minocycline for HIV+ Cognitive Impairment in Uganda
Conditions: HIV-associated Cognitive Impairment;   HIV Infections
Interventions: Drug: minocycline;   Drug: minocycline placebo capsule
3 Recruiting A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir/Ritonavir, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: TMC114 (darunavir);   Drug: ritonavir;   Drug: TMC125 (etravirine);   Drug: TMC278 (rilpivirine)
4 Completed A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers
Conditions: HIV;   HIV Infections
Interventions: Biological: Ad35-GRIN/ENV;   Biological: Ad35-GRIN
5 Unknown  Evaluating Post-test HIV Counseling Videos for Teens
Conditions: HIV;   HIV Infections
Intervention: Behavioral: Video
6 Completed
Has Results
Effects of Contingency Management for Methamphetamine Abstinence on Post-Exposure Prophylaxis for HIV in Men Who Have Sex With Men (MSM)
Conditions: Amphetamine-Related Disorders;   HIV;   HIV Infections
Interventions: Drug: Truvada;   Behavioral: CM
7 Active, not recruiting Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome
Conditions: HIV (Human Immunodeficiency Virus);   Metabolic Syndrome;   HIV Infections
Intervention: Behavioral: Dietary Intervention
8 Completed Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Be Proud! Be Responsible!;   Behavioral: Becoming A Responsible Teen (BART);   Behavioral: Reducing the Risk
9 Withdrawn Raltegravir Activity In Lymphoid Tissues
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Efavirenz + Tenofovir DF/Emtricitabine;   Drug: Raltegravir + Tenofovir DF/Emtricitabine;   Procedure: Colonoscopy with biopsies;   Procedure: Inguinal Lymph Node Excision
10 Completed
Has Results
Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
Conditions: HIV Infection;   HIV Infections
Intervention: Drug: Raltegravir
11 Completed Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Conditions: Acute HIV Infection;   HIV Infections
Intervention: Drug: Darunavir/Ritonavir and Etravirine
12 Completed The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
Conditions: HIV Positive;   Opioid Dependence;   Opioid Agonist Treatment;   HIV Infections
Intervention:
13 Recruiting Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?
Conditions: HIV Infection;   Herpes Simplex Type II;   HIV Infections
Interventions: Drug: valacyclovir;   Drug: Placebo
14 Withdrawn Pharmacotherapy for HIV Infected Patients With Alcohol Problems
Conditions: HIV Infection;   Heavy Alcoholic Consumption;   HIV Infections
Intervention: Drug: Naltrexone
15 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
16 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
17 Completed Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: darunavir;   Drug: Ritonavir;   Drug: Etravirine
18 Completed Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: AZT+3TC+ABV (Trizivir);   Drug: Switching to LPV/r monotherapy (Kaletra)
19 Completed Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
Conditions: HIV/HCV Co-infection;   HIV Infections
Interventions: Drug: Lopinavir/ritonavir;   Drug: Lopinavir/ritonavir with two nucleoside analogs
20 Active, not recruiting Strategic Timing of Antiretroviral Treatment
Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years